Trial intelligence / Profile preview

Phase II oxaliplatin plus capecitabine in recurrent metastatic breast cancer

2012-005329-56Phase 2Terminated

Sponsor: Department of Oncology
Start: May 2013
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
Countries: 1

Overview

Phase 2, open-label, single-arm trial of oxaliplatin and capecitabine in breast cancer, sponsored by Department of Oncology. Primary endpoint: Response rate. Started May 2013; status: terminated.

Drugs

oxaliplatincapecitabine

Conditions

breast cancer

Beyond the preview

Go deeper on 2012-005329-56.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2012-005329-56.